Melanoma

During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed dosing considerations and toxicity when choosing combination treatment for patients with melanoma. This is the second of 2 articles based on this event.

In an interview with Targeted Oncology, Howard D. Edington, MD, discussed Allegheny Health Network’s recently unveiled Melanoma and Skin Cancer Center and its new technology.

It is a promising time for cellular therapy, and combinations with gene modification or other systemic or local therapies bode well for solid tumor development of this TIL therapy platform.

During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed what patient factors and other considerations affect the choice of immunotherapy for patients with advanced BRAF-negative melanoma. This is the first of 2 articles based on this event.

The FDA has approved lifileucel, a tumor infiltrating lymphocyte therapy, for the treatment of advanced melanoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Evan J. Lipson, MD, and participants discussed tolerability factors that could influence the choice of frontline immunotherapy regimen for a patient with metastatic melanoma.

Dr Atkins discusses current unmet needs in the treatment landscape for metastatic melanoma and provides an overview of some of the treatments currently under investigation that show promise.

Insights about second-line treatment options for metastatic melanoma and discusses available data for treatment sequencing.

Immune-related adverse events are often a sign treatment is working. Dr Atkins discusses potential adverse events and how he counsels patients about them.

An expert perspective on how to best treat a patient diagnosed with stage IV BRAF-mutated melanoma.

Dr Atkins shares his approach to first-line treatment and reviews data regarding treatment sequencing from the DREAMseq Trial.

An overview of treatments for metastatic melanoma, including data updates regarding combination options.

Michael B Atkins, MD, shares insights on the prognosis of patient’s diagnosed with advanced melanoma and discusses the value of BRAF mutation testing.

Michael B. Atkins, MD, reviews a case involving a female patient who was diagnosed with stage IV BRAF-mutated melanoma, and shares insights on the patient’s prognosis and his approach to diagnosis.

Findings from 3-year follow-up of KEYNOTE-942/mRNA-4157-P201 show that the cancer vaccine mRNA-4157 plus pembrolizumab reduced the risk of recurrence or death in patients with stage III/IV melanoma following resection.

Hussein Tawbi, MD, PhD, closes his discussion by sharing some clinical pearls for fellow oncologists treating patients with metastatic melanoma.

A phase 1/2 study of KSQ-001EX will commence at MD Anderson Cancer Center following this investigational new drug approval from the FDA.

Hussein Tawbi, MD, PhD, explains that if a patient with metastatic melanoma and a BRAF mutation progresses after initial checkpoint inhibitors, either combination immunotherapy or MEK inhibitor therapy is considered, based on disease progression pace and pattern.

The phase 3 DREAMseq trial compared initial treatments of combination immunotherapy or BRAF/MEK inhibitors for B-Raf mutated melanoma, showing a 20% overall survival benefit at 2 years for immunotherapy as the first-line treatment.

Hussein Tawbi, MD, PhD, explains that for BRAF-mutated metastatic melanoma, treatment options include checkpoint inhibitors, single-agent and combination IO therapies, and BRAF and MEK inhibitor combinations, offering varying response rates and progression-free survival periods.

During a Targeted Oncology™ Case-Based Roundtable™ event, Douglas B. Johnson, MD, MSCI, reviewed data for safety and efficacy of immune checkpoint inhibition in patients with metastatic melanoma.

Hussein Tawbi, MD, PhD, presents the case of a 67-year-old woman with stage IV melanoma and shared his initial impressions.

Hussein Tawbi, MD, PhD, emphasizes the importance of patient education in managing adverse events from the treatment of metastatic melanoma with checkpoint inhibition, discussing symptom recognition, potential side effects, and treatment adjustments while ensuring team accessibility and patient communication.

RP2 demonstrated promising response rates and tolerability in the treatment of metastatic uveal melanoma, both as a monotherapy and in combination with nivolumab.

Over the past decade, the frontline treatment landscape for metastatic melanoma has evolved with studies like CheckMate-067 and KEYNOTE-006 highlighting the superiority of PD-1-based therapies over ipilimumab, and recent trials introducing new combination treatments.